• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Botulinum toxin use in patients with post-stroke spasticity: a nationwide retrospective study from France
ConclusionOur analysis of the exhaustive PMSI database showed a suboptimal implementation of BoNT-A treatment recommendations in France. BoNT-A treatment initiation and re-administration are low, particularly in patients with post-stroke spasticity. Further investigations may help explain this observation, and may target specific actions to improve spasticity-related care pathway.
Source: Frontiers in Neurology - August 23, 2023 Category: Neurology Source Type: research

Early versus late injections of Botulinumtoxin type A in post-stroke spastic movement disorder: A literature review
Toxicon. 2023 May 3:107150. doi: 10.1016/j.toxicon.2023.107150. Online ahead of print.ABSTRACTPost-stroke spastic movement disorder (PS-SMD) is one of the main causes of severe disability in the chronic phase after stroke. The prevalence of SMD rises up with time after stroke to more than 28% in the chronic phase, and its secondary complications such as contracture, abnormal postures and/or movement patterns, spasticity-associated pain, also increases with time after stroke when physical and medical management of PS-SMD had been delayed in the early stroke phase. It has been published by several controlled studies that the...
Source: Toxicon - May 5, 2023 Category: Toxicology Authors: J örg Wissel Songjin Ri Anatol Kivi Source Type: research

Po-01-167 efficacy of botulinum toxin type a (agn-151607) for the prevention of postoperative atrial fibrillation in cardiac surgery patients: atrial fibrillation and anticoagulation results from the phase 2 nova study
Oral anticoagulation reduces the risk of stroke but also increases the risk of bleeding. Prevention of post-operative atrial fibrillation (POAF) could result in a lower burden of oral anticoagulation and bleeding events. AGN-151607 has been proposed to prevent POAF and its safety/efficacy was tested in a multicenter randomized trial.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Nathan Waldron, Alexandra OSullivan, Jonathan P. Piccini, Matthew Romano, Pierre Voisine, Wilson Titanji, Richard Leaback, William Ferguson, Jonathan S. Steinberg Source Type: research

Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study
This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect...
Source: Frontiers in Neurology - April 6, 2023 Category: Neurology Source Type: research

Safety and efficacy of MT10107 in post-stroke upper limb spasticity treatment: A phase I randomized controlled trial
Conclusion: The safety and efficacy of MT10107 showed no significant difference compared to onabotulinumtoxinA in post-stroke upper limb spasticity treatment.
Source: Medicine - November 4, 2022 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Clinical Onset of Action of Incobotulinum Toxin A Preparation
CONCLUSION: This study demonstratedthe onset of IncobotulinumtoxinA efficacy started after 7 days; this rapid action and efficacy of BoNT/A preparation could improve an intensive rehabilitation program after some days post injection. Early clinical onset of action could be by the absence of complexing proteins in the preparation.PMID:35786195 | DOI:10.2174/1871527321666220630154404
Source: CNS and Neurological Disorders Drug Targets - July 5, 2022 Category: Drugs & Pharmacology Authors: Riccardo Marvulli Maurizio Ranieri Laura Belinda Rizzo Francesco Marra Giancar Lo Ianieri Marisa Megna Source Type: research

A systematic review on extracorporeal shock wave therapy and botulinum toxin for spasticity treatment: a comparison on efficacy
CONCLUSIONS: A beneficial effect on spasticity was found for both treatments: evidence showed that ESWT and BoNT-A can ameliorate spasticity considering parameters such as MAS, MTS, AROM, PROM, UE-FMA, VAS and SFS in post-stroke, multiple sclerosis, and cerebral palsy patients. Further research is required to strengthen the evidence, and more suitable study protocols are highly needed.PMID:35412036 | DOI:10.23736/S1973-9087.22.07136-2
Source: European Journal of Physical and Rehabilitation Medicine - April 12, 2022 Category: Rehabilitation Authors: Emanuela E Mihai Marius N Popescu Alina N Iliescu Mihai Berteanu Source Type: research

Pages: 1  2  3  4  5  6